Last reviewed · How we verify
Tiselizumab
Tiselizumab is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 2 development.
Tislelizumab is a medication being studied in clinical trials for various conditions, including Small Cell Lung Cancer (SCLC), Follicular Lymphoma, Lung Cancer, Classic Hodgkin Lymphoma, and Cancer. It is being investigated as a treatment in combination with other medications, such as Anlotinib and Irinotecan, in a clinical trial for SCLC.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tiselizumab |
|---|---|
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (PHASE3)
- Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab (PHASE1, PHASE2)
- Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma (PHASE2)
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma (PHASE3)
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (PHASE2)
- Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiselizumab CI brief — competitive landscape report
- Tiselizumab updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI
Frequently asked questions about Tiselizumab
What is Tiselizumab?
Who makes Tiselizumab?
What development phase is Tiselizumab in?
Related
- Manufacturer: Tianjin Medical University Cancer Institute and Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing